MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma

Dr. Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, presents the latest poster on EasyM, a novel clonotypic peptides mass spectrometry blood test for MRD monitoring, at the annual ASH 2023 conference.

In this study, EasyM mass spectrometry-based MRD was demonstrated to predict outcomes following autologous stem cell transplantation (autoSCT) in multiple myeloma (MM). EasyM was able to successfully predict progression-free survival (PFS) by quantifying measurable residual disease (MRD) in peripheral blood at Day 100 post-autoSCT.